Table 1.
Open in new tab

Clinical and demographic parameters of the Crohn’s disease [CD] [left] and ulcerative colitis [UC] [right] cohorts

ParameterUC cohort [N = 50]CD cohort [N = 98]Odds ratiop-value
Gender male [n, %]24 [48]59 [60.2]2.260.014
Age [median ± IQR, years]37 [34.0–46.9]35 [31.7–38.0]—0.008
Disease duration [median ± IQR, years]9.5 [6–18]8 [3–15]—0.049
Median age at diagnosis [median ± IQR, years]26 [21.0–40.5]23 [18–36]—0.017
Median weight at induction [median ± IQR, kg]67 [59.5–81.5]67 [59.3–79]——
Median BMI at induction [median ± IQR]21.7 [19.4–26.3]22.8 [20.4–25.3]——
Concomitant immunomodulator therapy [n, %]7 [14]24 [24.6]1.990.14
Concomitant steroid therapy [n, %]3 [6]14 [14.3]2.610.14
Extra-intestinal manifestations [n, %]17 [48]30 [30.6]0.850.67
Smoking at induction [n, %]1 [3.0]20 [20.4]12.560.015
Smoking at diagnosis [n, %]3 [10.3]21 [21.4]4.270.024
Comorbidities [n, %]19 [55.8]21 [21.4]0.440.033
Prior immunomodulator therapy [n, %]26 [54.1]61 [62.0]1.390.35
Prior infliximab therapy [n, %]19 [39.5]35 [36.0]1.160.86
ParameterUC cohort [N = 50]CD cohort [N = 98]Odds ratiop-value
Gender male [n, %]24 [48]59 [60.2]2.260.014
Age [median ± IQR, years]37 [34.0–46.9]35 [31.7–38.0]—0.008
Disease duration [median ± IQR, years]9.5 [6–18]8 [3–15]—0.049
Median age at diagnosis [median ± IQR, years]26 [21.0–40.5]23 [18–36]—0.017
Median weight at induction [median ± IQR, kg]67 [59.5–81.5]67 [59.3–79]——
Median BMI at induction [median ± IQR]21.7 [19.4–26.3]22.8 [20.4–25.3]——
Concomitant immunomodulator therapy [n, %]7 [14]24 [24.6]1.990.14
Concomitant steroid therapy [n, %]3 [6]14 [14.3]2.610.14
Extra-intestinal manifestations [n, %]17 [48]30 [30.6]0.850.67
Smoking at induction [n, %]1 [3.0]20 [20.4]12.560.015
Smoking at diagnosis [n, %]3 [10.3]21 [21.4]4.270.024
Comorbidities [n, %]19 [55.8]21 [21.4]0.440.033
Prior immunomodulator therapy [n, %]26 [54.1]61 [62.0]1.390.35
Prior infliximab therapy [n, %]19 [39.5]35 [36.0]1.160.86

IQR, interquartile range; BMI, body mass index.

Table 1.
Open in new tab

Clinical and demographic parameters of the Crohn’s disease [CD] [left] and ulcerative colitis [UC] [right] cohorts

ParameterUC cohort [N = 50]CD cohort [N = 98]Odds ratiop-value
Gender male [n, %]24 [48]59 [60.2]2.260.014
Age [median ± IQR, years]37 [34.0–46.9]35 [31.7–38.0]—0.008
Disease duration [median ± IQR, years]9.5 [6–18]8 [3–15]—0.049
Median age at diagnosis [median ± IQR, years]26 [21.0–40.5]23 [18–36]—0.017
Median weight at induction [median ± IQR, kg]67 [59.5–81.5]67 [59.3–79]——
Median BMI at induction [median ± IQR]21.7 [19.4–26.3]22.8 [20.4–25.3]——
Concomitant immunomodulator therapy [n, %]7 [14]24 [24.6]1.990.14
Concomitant steroid therapy [n, %]3 [6]14 [14.3]2.610.14
Extra-intestinal manifestations [n, %]17 [48]30 [30.6]0.850.67
Smoking at induction [n, %]1 [3.0]20 [20.4]12.560.015
Smoking at diagnosis [n, %]3 [10.3]21 [21.4]4.270.024
Comorbidities [n, %]19 [55.8]21 [21.4]0.440.033
Prior immunomodulator therapy [n, %]26 [54.1]61 [62.0]1.390.35
Prior infliximab therapy [n, %]19 [39.5]35 [36.0]1.160.86
ParameterUC cohort [N = 50]CD cohort [N = 98]Odds ratiop-value
Gender male [n, %]24 [48]59 [60.2]2.260.014
Age [median ± IQR, years]37 [34.0–46.9]35 [31.7–38.0]—0.008
Disease duration [median ± IQR, years]9.5 [6–18]8 [3–15]—0.049
Median age at diagnosis [median ± IQR, years]26 [21.0–40.5]23 [18–36]—0.017
Median weight at induction [median ± IQR, kg]67 [59.5–81.5]67 [59.3–79]——
Median BMI at induction [median ± IQR]21.7 [19.4–26.3]22.8 [20.4–25.3]——
Concomitant immunomodulator therapy [n, %]7 [14]24 [24.6]1.990.14
Concomitant steroid therapy [n, %]3 [6]14 [14.3]2.610.14
Extra-intestinal manifestations [n, %]17 [48]30 [30.6]0.850.67
Smoking at induction [n, %]1 [3.0]20 [20.4]12.560.015
Smoking at diagnosis [n, %]3 [10.3]21 [21.4]4.270.024
Comorbidities [n, %]19 [55.8]21 [21.4]0.440.033
Prior immunomodulator therapy [n, %]26 [54.1]61 [62.0]1.390.35
Prior infliximab therapy [n, %]19 [39.5]35 [36.0]1.160.86

IQR, interquartile range; BMI, body mass index.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close